Over the past decade, pull incentives as a solution to the broken antibiotic market have been proposed to entice companies into antibiotic research and development. These incentives would essentially provide a market, and therefore a return on investment for pharmaceutical companies. Almost all of today’s inadequate antibiotic pipeline is provided by biotech and small pharma. All are threatened with loss of investor interest because of the failed marketplace and many are experiencing difficulty in raising funds either from public or private markets. One alternative to providing money to the “evil” pharmaceutical industry via a substantial pull incentive is to create publicly funded non-profit organizations or public-private ventures that would essentially replace the industry in antibiotic research, development and commercialization. Two proponents of this approach are Lord Jim O’Neill (of the O’Neill Commission or Antimicrobial Resistance Review fame) and Ramanan Laxminarayan of the Center for Disease Dynamics, Economics and Policy and of GARDP. Both, clearly, are key thought leaders in the area.
Biopharma Policies, Regulations
Section: Biopharma Insights View all sections
Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is to become a leading international organization for advancing artificial intelligence innovations in Drug Discovery, Clinical Research, Diagnostics, Precision Medicine and other key areas of pharmaceutical research and healthcare. The newly formed alliance will be a voice of the industry in matters of education, lobbying for policies and regulations, facilitating investment, and promoting AI-innovations among top drug makers and healthcare institutions.
China has been becoming a research powerhouse in many fields of science, but it still is a minor player when it comes to pharmaceuticals. However, recent developments suggest that China’s role in pharmaceutical research may change in the near future.
Immunotherapies are hot property. Immuno-oncology is the crown jewel. But the road to riches, and more importantly cancer cures, is now crowded and full of potholes. Drug hunters need to look ahead, beyond the discovery process itself, to the reality of the many impediments that will confront drug candidates as they proceed towards the clinic in today's landscape. Here, I present three insights from current events, the third one taking a contrarian position.